CLOs on the Move


 
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akebia.com
  • 245 First Street Suite 1400
    Cambridge, MA USA 02142
  • Phone: 617.871.2098

Executives

Name Title Contact Details
Sarah Whipple
VP, Legal and Chief Compliance Officer Profile
Molly Shea
Head of Regulatory Affairs Profile
Henry Gu
Vice President, Chief Intellectual Property Counsel Profile
Andrea Paul
Vice President, Legal - Corporate and Securities Profile
Laura Graham
Director, Corporate Counsel Profile

Similar Companies

Genera Energy

Genera Energy provides a robust and integrated biomass supply solution for the advanced biofuels, biopower, and biobased products industries.

LyGenesis

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient`s lymph nodes to be used as bioreactors to regrow functioning ectopic organs.

Nventa Biopharmaceuticals Corporation

Nventa Biopharmaceuticals Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morphogenesis

Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.

Outpost Medicine

At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). ​Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.